Company Profile

Avalo Therapeutics Inc (AKA: Ceregen Corporation~Cerecor Inc)
Profile last edited on: 5/15/2023      CAGE: 6GKF2      UEI: J7WVEQTH1ML6

Business Identifier: Treatment of immune dysregulation: developing therapies that target LIGHT-signaling network.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

540 Gaither Road Suite 400
Rockville, MD 20850
   (410) 522-8707
Location: Single
Congr. District: 08
County: Montgomery

Public Profile

Previously doing business as Ceregen Corporation, renamed Cerecor Inc. (NASDAQ:CERC) - with facilities in Rockville, MD and in Wayne PA - having two Phase I NIH projects in its earlier days and a totally different management team, the firm has radically shifted focus since going public in 2015. Eighteen months after completing its merger with Aevi Genomic Medicine, Cerecor rebranded as Avalo Therapeutics. The merger with Aevi had provided Cerecor with what was described as a “clean break” from company’s past history with diseases of the central nervous system. Firm is now focus on developing precision medications for its core areas of focus. In addition to the break with the therapeutic focus, merger also provided the company with a new leadership team. Renamed a second time, as of August 2021 the firm is now doing business as Avalo Therapeutics indicated by the principals as better to reflect the firm's increased - and shifted - focus on immunology, immuno-oncology, and rare genetic diseases.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Michael Cola -- Chief Executive Officer, Chairman of the Board

  Robert C Moscato Jr -- President, Chief Operating Officer and Director

  Garry Neil -- Chairman, President & CEO: formerly Chief Scientific Officer

  Blake Paterson -- Co-Founder & CEO, Director

  Isaac Blech -- Founder and Director

  John Boland -- Vice President, Clinical Operations

  Heather Fraser -- VP Clinical Operations & Project Management

  Schond L Greenway -- Chief Financial Officer

  James A Harrell Jr -- Chief Commercial Officer

  Lisa Hegg -- Senior Vice President, Program Management and Corporate Infrastructure

  John Kaiser -- VP Commercialization and Business Development

  Ronald N Marcus

  Colleen Matkowski -- Senior Vice President, Global Regulatory Affairs and Quality Assurance

  Reza Mazhari -- VP Drug Discovery & Development

  Dino C Miano -- Senior Vice President, CMC and Technical Operations

  Mariam E Morris -- Chief Financial Officer

  Federica F O'Brien -- Former CFO

  Matthew V Phillips -- Chief Commercial Officer

  Christopher Ryan Sullivan -- Chief Financial Officer

  Robert E Swedberg -- Vice President, Finance and Corporate Controller

  John Vornov -- SVP Clinical Development & Regulatory Affairs